International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Study on Bilayer Tablet to Enhance Patient Compliance

Mr. Swapnil Bagde[1], Ms. Simran Gajbhiye[2], Mr. Praghyanshu Ramteke[3], Dr. Surendra Pardhi[4]

[1,2,3]M. Pharmacy Student of Institute of Pharmaceutical Science & Research, Balaghat (M.P.)
[4]Professors of Institute of Pharmaceutical Science & Research, Balaghat (M.P.)

Abstract
Most of the patient suffer disease like, hear disease, diabetic etc. and they required multiple medication. From these requirement we get idea to study on bilayer tablet. To consider this objective our study wprk titled as "Study on Bilayer tablet to enhance patient compliance". Bilayer tablets have emerged as an innovative and efficient oral dosage form, designed to meet the growing need for controlled drug release, combination therapy, and improved patient compliance. These tablets consist of two distinct layers, each formulated with a specific purpose—typically an immediate release (IR) layer for rapid therapeutic effect and a sustained release (SR) layer for prolonged action. Alternatively, bilayer tablets can be used to deliver two different drugs simultaneously, particularly in fixed-dose combinations (FDCs), where each layer may contain a separate active pharmaceutical ingredient (API). These review study was performed during study in M.Pharma. at Institute of Pharmaceutical Science & Research, Balaghat (M.P.). These study cover the recent trend, future aspect, mechanism of bilayer tablet, material selection criteria, Specialized bilayer rotary tablet press machines operation, excipient-excipient compatibility study, drug-excipient compatibility and evaluation criteria's for bilayer tablet. After review of several literatures it was concluded that bilayer tablet is in demand to cost saving formulation and enhance the patient compliance.

Keywords Bilayer Tablet, Immediate Release, Sustained Release, Fixed-Dose Combinations

Introduction

A bilayer tablet is a tablet that consists of two separate layers pressed together, where each layer may contain different active pharmaceutical ingredients (APIs) or the same API with a different function (e.g., immediate release vs. sustained release).

Key Characteristics:

Two layers are clearly visible or distinguishable.

Can be formulated with:

- Same drug, but different release kinetics.
- Two different drugs, with separate mechanisms or compatibility needs.

Each layer is compressed separately, and then joined during the final compression stage.

Types of Bilayer Tablets

Bilayer tablets are categorized based on their function, drug release profile, and drug content. Here are the major types:

1. Based on Drug Release Profile:

a. Immediate Release (IR) + Sustained Release (SR)

Most common type

One layer releases the drug quickly for rapid onset, while the second layer maintains the drug effect over a long period.

Example: Nicardipine (IR) + Atenolol (SR)

b. Sustained Release + Sustained Release

Both layers release the drug slowly but at different rates or locations in the gastrointestinal tract.

Useful when the drug has a long half-life or needs prolonged action.

c. Delayed Release + Immediate Release

The delayed release layer resists gastric conditions and releases the drug in the intestine, while the IR layer acts quickly. Often used for drugs unstable in acidic pH.

2. Based on Drug Content:

a. Single API, Dual Release

Same drug in both layers with different release rates (IR + SR).

Allows biphasic plasma concentration.

b. Dual API (Fixed Dose Combination)

Two different drugs in separate layers.

Used to combine therapy and avoid interaction between incompatible drugs.

3. Based on Therapeutic Purpose:

a. Chronotherapeutic Bilayer Tablets

Designed for diseases with circadian rhythm, such as asthma or arthritis.

One layer provides immediate relief, the other provides delayed action to match body clock.

b. Gastroretentive Bilayer Tablets

One layer swells to float or adhere in the stomach, the other provides drug release.

Useful for local stomach treatment or drugs absorbed in upper GI tract.

4. Press-Coated or Sandwich Tablets (Modified Bilayer)

A core tablet is surrounded or sandwiched by a second drug layer.

Enhances drug protection, taste masking, or delayed release.

Mechanism of Bilayer Tablets

The mechanism of action of a bilayer tablet depends on the design of each layer, which can be tailored for specific release profiles, site of action, or combination therapy.

1. Immediate Release (IR) Layer Mechanism

Disintegrates quickly upon contact with gastric fluids.

Releases the active drug rapidly for fast therapeutic action.

Often contains superdisintegrants (e.g., Crospovidone, Sodium Starch Glycolate).

Mechanism:

Tablet reaches stomach.

IR layer swells and breaks apart quickly.

Drug dissolves and gets absorbed rapidly in GI tract.

2. Sustained/Controlled Release (SR/CR) Layer Mechanism

Releases the drug gradually over time.

Maintains a steady plasma concentration for extended periods.

Uses hydrophilic polymers (e.g., HPMC), hydrophobic matrices, or coating systems.

Mechanism:

After IR layer disintegration, the SR layer retains its form.

Water penetrates the SR layer → forms gel barrier.

Drug diffuses slowly through the hydrated matrix or dissolves and erodes gradually.

Controlled absorption into bloodstream.

3. Dual Drug Layer Mechanism

Each layer contains a different drug.

Drugs may act at different sites (e.g., stomach vs intestine) or on different receptors.

Helps avoid incompatibility and allows fixed-dose combinations.

Mechanism:

Each drug layer dissolves and releases independently.

May have separate absorption pathways or targets.

4. Chronotherapeutic Bilayer Mechanism

Designed to match the body's biological clock.

First layer acts immediately, second layer releases drug after a lag time.

Used for time-sensitive conditions (e.g., asthma at night, arthritis in morning).

Mechanism:

IR layer releases drug quickly.

Delay layer resists dissolution (using enteric coating or special polymers).

After lag time, delayed layer erodes/releases drug in a targeted region (e.g., intestine).

Need of Bilayer Tablets

Bilayer tablets are pharmaceutical dosage forms consisting of two distinct layers, each designed to perform a specific function. The development of bilayer tablets addresses several formulation and therapeutic needs. Below are the main reasons why bilayer tablets are used:

1. Controlled or Sustained Drug Release

One layer can provide immediate release (IR) for rapid onset of action.

The second layer can provide sustained or controlled release (SR/CR) to maintain drug levels for an extended period.

This avoids the need for multiple doses throughout the day.

2. Combination of Incompatible Drugs

Bilayer tablets allow the separation of chemically or physically incompatible drugs within one tablet by placing them in different layers.

This improves stability and safety.

3. Dual Action or Biphasic Release

The same drug can be delivered in two phases:

Immediate effect from the first layer.

Maintenance effect from the second layer.

Example: Nicardipine (IR) + Atenolol (SR) in hypertension management.

4. Patient Compliance

Fewer tablets mean easier administration, especially for chronic patients.

Enhanced therapeutic efficacy and reduced side effects increase patient adherence.

5. Flexibility in Drug Delivery Design

Different release profiles can be designed and tailored in a single dosage form.

Ideal for polypharmacy conditions like diabetes, hypertension, or cardiovascular diseases.

6. Lifecycle Management

Extending the patent life of a drug by offering an innovative delivery system.

Provides a way to differentiate the product in the market.

7. Reduction in Gastrointestinal Side Effects

Gradual release avoids high local concentration in the stomach.

This helps in minimizing irritation and improving gastric tolerance.

Advantages and Disadvantages of Bilayer Tablets

Bilayer tablets offer a modern solution for improving drug delivery, but they also come with certain formulation and manufacturing challenges.

Advantage	Description
1. Dual Drug Delivery	Can deliver two different drugs with different mechanisms or absorption profiles.
2. Biphasic Drug Release	One layer for immediate release (IR) and the other for sustained release (SR), improving therapeutic effect.
3. Improved Patient Compliance	Reduces the number of tablets needed per day (especially in chronic diseases).
4. Separation of Incompatible Drugs	Physically separates incompatible drugs in different layers to prevent interaction.
5. Cost-Effective	Combination therapy in a single tablet reduces packaging and administration costs.
6. Lifecycle Management	Helps pharmaceutical companies extend patent life and create new product lines.
7. Customized Therapy	Allows for targeted and time-based release, useful in chronotherapy.

Disadvantage	Description
1. Complex Manufacturing	Requires specialized bilayer compression machines and strict quality control.
2. Layer Separation Risk	Poor bonding between layers may cause separation during handling.
3. Drug Migration	One drug may migrate into the other layer over time, affecting stability.
4. Limited Drug Compatibility	Only suitable drugs or layers can be compressed and processed together.

Disadvantage	Description
5. Higher Production Cost	Equipment ,process validation are more expensive than conventional tablets.
6. Technical Challenges in Scale-Up	Difficult to scale up from lab to industrial scale while maintaining uniformity and performance.

Material & Methods

Preparation method of Bilayer tablet

The preparation of bilayer tablets involves formulating and compressing two separate layers, each with its own drug release characteristics or composition. This process requires precision to ensure layer integrity, uniformity, and controlled release.

Step-by-Step Process to Prepare Bilayer Tablets

1. Preformulation Studies

Identify the physicochemical properties of each drug (solubility, stability, compatibility).

Select excipients suitable for immediate or sustained release, as needed.

2. Formulation Design

Layer 1 (Immediate Release): Use superdisintegrants, water-soluble fillers (e.g., lactose), and binders.

Layer 2 (Sustained Release): Use hydrophilic (HPMC) or hydrophobic (EC) polymers, along with controlled-release agents.

Determine drug-excipient compatibility (e.g., via FTIR, DSC).

3. Granulation

Prepare each layer's granules separately:

Wet granulation or dry granulation or direct compression.

Dry, sieve, and lubricate both granule batches.

4. Compression Using Bilayer Tablet Press

Use a bilayer rotary tablet press with two feeding stations:

First layer powder is filled and lightly compressed (precompression).

Second layer powder is added on top.

Final compression binds both layers into one compact.

Ensure proper interlayer adhesion to prevent delamination.

5. Packaging

Use moisture-proof, light-resistant packaging to ensure stability.

Label with drug contents, layer type, and release profile.

Example Formulation for Bilayer Tablet:

Layer	Ingredients	Function
IR Layer	Drug A, Crospovidone, Lactose, MCC	Fast action
SR Layer	Drug B, HPMC, EC, Magnesium Stearate	Prolonged effect

Precuation to Avoid Issues

Maintain optimal compression force to avoid layer separation.

Use binding agents in both layers if required for cohesion.

Check for moisture content, which can affect tablet integrity.

Excipient Selection Criteria for Bilayer Tablets

In bilayer tablet formulation, selecting suitable excipients is critical for ensuring tablet integrity, layer compatibility, and desired drug release profiles. Each layer may require different excipients depending on whether it is for Immediate Release (IR) or Sustained Release (SR).

1. General Selection Criteria for All Excipients

Criterion	Description
Compatibility	Should be chemically and physically compatible with APIs and other excipients.
Compressibility	Must ensure proper tablet strength and prevent capping or lamination.
Flow Properties	Must flow well for uniform die filling, especially in rotary tablet presses.
Moisture Content	Should be low and controlled to prevent drug degradation.
Stability	Should be stable under manufacturing and storage conditions.
Non-reactivity	Must not react with APIs or other components.
Safety (GRAS Status)	Should be Generally Recognized as Safe for use in oral formulations.

2. Selection Criteria for IR Layer Excipients

Type	Role	Example Excipients	Selection Basis
Diluent	Adds bulk	Lactose, MCC, DCP	Good compressibility
Binder	Improves granule cohesion	PVP K30, Starch paste	Water/alcohol soluble
Disintegrant	Promotes rapid breakdown	Crospovidone, SSG, CCS	Fast action, effective at low concentration
Lubricant	Prevents sticking to punch	Magnesium stearate	Used in small amount
Glidant	Enhances powder flow	Talc, Colloidal silica	Improves feed into die cavity

3. Selection Criteria for SR Layer Excipients

Type	Role	Example Excipients	Selection Basis
Matrix Former	Controls drug release	HPMC, EC, Carbopol	Gel-forming or hydrophobic
Release Modifier	Adjusts drug release kinetics	Lactose, Mannitol	To modify porosity and erosion
Binder	Maintains mechanical strength	PVP, HPMC	Compatible with matrix
Lubricant	Reduces die wall friction	Magnesium stearate	Low concentration to avoid retarding release

Type	Role	Example Excipients	Selection Basis
Hydrophobic Agents	Slow down water penetration	Stearic acid, Wax	For hydrophobic matrices

4. Additional Considerations

Factor	Impact on Excipient Selection
API Solubility	Highly soluble drugs need stronger matrices (e.g., HPMC) to control burst release.
Drug Dose	High-dose drugs need excipients with excellent compressibility to reduce tablet size.
Desired Release Mechanism	Diffusion-based (hydrophilic), erosion-based (hydrophobic), or both.
Drug Sensitivity (to pH, light)	May require coated granules or protective excipients.
Process Type (wet or direct compression)	Affects the binder, disintegrant, and lubricant choice.

Drug Selection Criteria for Bilayer Tablets

Choosing the right drug(s) is critical in bilayer tablet formulation, as the design relies on specific pharmacokinetic and pharmacodynamic characteristics. The selected drug(s) must be suitable for layered delivery, whether for dual release, combination therapy, or chronotherapeutics.

1. General Criteria for Drug Selection

Parameter	Description
Dose	Suitable for tablet form (generally ≤ 500 mg per layer).
Therapeutic Need	Drug should benefit from immediate and sustained release, or dual-drug therapy.
Half-life	Drugs with a short half-life are ideal for SR layers to prolong activity.
Bioavailability	Drugs with moderate to high oral bioavailability are preferred.
Absorption Window	Should be absorbed throughout the GI tract (esp. for SR layers).
Drug-Drug Compatibility	No chemical or physical incompatibility between drugs if used in separate layers.
Stability	Stable during granulation, compression, and storage conditions.
Solubility	Highly soluble drugs require stronger matrix formers to control release.
Therapeutic Index	Preferably drugs with a wide therapeutic window to reduce toxicity risk in modified release.

2. Criteria for Immediate Release (IR) Layer Drug

Parameter	Description
Rapid Onset Needed	For drugs used in pain relief, hypertension, asthma, etc.
Short Half-Life	Allows for fast action, followed by sustained effect via SR layer.
Good Aqueous Solubility	Ensures quick dissolution and absorption.
Low First-Pass Metabolism	Better systemic availability.

3. Criteria for Sustained Release (SR) Layer Drug

Parameter	Description
Short Biological Half-life	To avoid frequent dosing (ideal 2–5 hours).
Chronic Use	Drugs for chronic conditions (e.g., BP, diabetes).
Stable in GI Fluids	Must resist degradation in acidic and alkaline pH.
Linear Pharmacokinetics	Predictable absorption even with extended release.

4. Criteria for Dual Drug Combination (FDC) Bilayer Tablets

Parameter	Description
Complementary Mechanism	Drugs should act on different targets or pathways for synergistic effect.
Same Indication	Both drugs should treat the same disease (e.g., hypertension, diabetes).
Matching Pharmacokinetics	Similar duration of action to ensure consistent therapy.
No Physical/Chemical Incompatibility	Stable when compressed in adjacent layers.

Formulation of Bilayer Tablet: API-1+ API-2

Layer 1: Immediate Release (API-1)

Ingredient	Quantity per tablet (mg)	Function
API-1	10.0	Active drug
Microcrystalline Cellulose (MCC)	40.0	Diluent
Crospovidone	8.0	Superdisintegrant
PVP K30 (in IPA)	5.0	Binder (wet granulation)
Talc	2.0	Glidant
Magnesium Stearate	1.5	Lubricant

Ingredient	Quantity per tablet (mg)	Function
Total	66.5 mg	

Layer 2: Sustained Release (API-2)

Ingredient	Quantity per tablet (mg)	Function
API-2	50.0	Active drug
HPMC (K100M)	30.0	Sustained release polymer
Ethyl Cellulose	20.0	Hydrophobic matrix
Lactose	35.0	Filler
Talc	2.5	Glidant
Magnesium Stearate	2.0	Lubricant
Total	139.5 mg	

Final Tablet Weight:
66.5 mg (IR Layer) + 139.5 mg (SR Layer) = 206 mg

Compression Procedure:
Prepare granules for each layer separately via wet or dry granulation.
Compress the IR layer (API-1) lightly on bilayer tablet machine.
Add SR layer (API-2) granules and perform final compression.

Equipment selection for bilayer tablet

1. Bilayer Rotary Tablet Press Machine (Main Equipment)

A high-speed rotary press with two separate feeding systems and compression stages.
First layer is lightly pre-compressed, second layer is added, and final compression is applied to bond both layers.

Feature	Function
Dual Hopper System	For feeding two different granule blends for IR and SR layers.
Pre-Compression Station	Light compression of the first layer before second layer addition.
Final Compression Station	High-pressure compression of both layers into a single tablet.
Weight & Thickness Control	Ensures uniformity of each layer and total tablet.
Force Monitoring System	Maintains layer bonding and avoids delamination.

2. Supporting Equipment

Equipment	Use
Granulator (Rapid Mixer or Fluid Bed)	To prepare granules for each layer.
Drying Equipment (Tray or Fluid Bed Dryer)	To remove moisture from wet granules.

Equipment	Use
Sieving Machine	To obtain uniform particle size.
Blender (Double Cone, V-blender)	For homogeneous mixing of granules and excipients.
Dust Extractor	To minimize powder loss and maintain cleanliness.

3. Advanced Features in Modern Bilayer Machines

Auto-weight control system
Touchscreen HMI & SCADA connectivity
Automatic rejection of faulty tablets
Online thickness & hardness monitoring

Important Considerations When Choosing a Bilayer Tablet Machine

Factor	Importance
Compression force range	Ensures proper bonding between layers
Hopper & feeder design	Prevents cross-contamination
Tablet size capability	Should match formulation requirements
Ease of cleaning & maintenance	For compliance and efficiency
Production capacity	Based on batch size and output needs

Evaluation Test Procedures for Bilayer Tablets

Bilayer tablets must undergo comprehensive evaluation to ensure quality, performance, and layer integrity. The evaluation includes physical, chemical, and performance tests as per pharmacopeial standards (IP, USP, BP).

1. General Physical Evaluation Tests

Test	Purpose	Procedure
Appearance	To check color, shape, and surface finish of both layers	Visual inspection
Tablet Thickness	To ensure uniform compression	Use Vernier calipers or thickness gauge
Hardness (Crushing strength)	To assess mechanical strength	Use Monsanto or Pfizer hardness tester
Friability	To determine resistance to abrasion	Roche Friabilator (25 rpm for 4 minutes, ≤1% weight loss acceptable)
Weight Variation	To ensure uniform content	Weigh 20 tablets individually and compare with average (±5–10% limit)
Layer Separation/Delamination	To ensure interlayer bonding	Visually inspect after mechanical stress or during friability testing

2. Disintegration Test (for IR Layer)

Parameter	Description
Purpose	To check how quickly the IR layer breaks down
Procedure	Use USP disintegration test apparatus in 900 mL water at 37°C. Remove tablet after IR layer disintegrates. Max time: 15 minutes (as per IR specifications).

3. Dissolution Test

Evaluate both layers separately (IR and SR components).

a. Immediate Release Layer:

Apparatus: USP Type II (Paddle)
Medium: 900 mL water or specified buffer
Speed: 50–75 rpm
Time: 30–45 minutes
Analysis: Collect samples at specific intervals and analyze by UV/ HPLC

b. Sustained Release Layer:

Apparatus: USP Type I (Basket) or Type II
Medium: 900 mL buffer (e.g., pH 6.8 phosphate buffer)
Speed: 50 rpm
Time: Up to 12 or 24 hours
Analysis: Collect samples at 1, 2, 4, 6, 8, 12, and 24 hours

Note: IR layer may be evaluated in first 30 mins, followed by evaluation of SR layer after IR has released.

4. Content Uniformity

Parameter	Description
Purpose	To ensure uniform drug distribution in each tablet
Method	Assay 10 tablets individually using UV or HPLC
Acceptance	85–115% of labeled claim (USP standard)

5. Assay (Drug Content Estimation)

Purpose	To quantify the exact drug amount in each layer
Procedure	Crush tablet, dissolve in suitable solvent, filter, and analyze using UV-Visible spectrophotometer or HPLC.

6. Stability Testing

Purpose	To assess tablet behavior under stress conditions
Conditions	25°C/60% RH (long term), 40°C/75% RH (accelerated)
Duration	3 to 6 months
Parameters	Appearance, hardness, drug content, dissolution, and delamination

Limit of all evaluation parameter as per regulatory guideline

Test	Purpose	Standard/Limit
Appearance	Physical check	Uniform and defect-free
Thickness	Compression consistency	±5% of standard
Hardness	Mechanical strength	4–8 kg/cm² (typical)
Friability	Resistance to chipping	<1% weight loss
Weight Variation	Dose uniformity	±5% (avg. weight >250 mg)
Disintegration	IR layer breakdown	<15 minutes
Dissolution	Drug release profile	As per USP/monograph
Content Uniformity	Consistent drug content	85–115% of label claim
Assay	Actual drug content	95–105% (USP)

Current Trends in Bilayer Tablet Technology (2024–2025)

Bilayer tablets have evolved into a highly strategic dosage form in the pharmaceutical industry. With advancements in formulation technology, regulatory interest, and patient-centered care, the current trends in bilayer tablet development focus on improving drug delivery efficiency, patient compliance, and product differentiation.

1. Fixed-Dose Combinations (FDCs) for Chronic Diseases

Growing demand for bilayer tablets in hypertension, diabetes, cardiovascular diseases, and HIV/AIDS.

Combines two synergistic drugs in one tablet (e.g., Metformin + Glibenclamide, Amlodipine + Losartan).

Reduces pill burden, improves compliance, and supports government health programs.

2. Dual-Release Profiles (IR + SR)

Increasing use of bilayer tablets to combine immediate and sustained release for single-drug therapy.

Examples: Pain management, antihypertensives, antidepressants.

Delivers fast onset followed by controlled therapeutic effect over 12–24 hours.

3. Personalized and Chronotherapeutic Dosage Forms

Bilayer tablets tailored for chronotherapy (e.g., asthma, arthritis, and hypertension).

Designed to release drug in sync with circadian rhythms (e.g., night-time release for morning symptoms).

Trend toward time-controlled delivery layers using special polymers or coatings.

4. Advanced Manufacturing Technologies

Use of automated bilayer rotary tablet presses with:

Online layer weight control

In-process monitoring

Minimal cross-contamination

Enhanced layer adhesion techniques to prevent delamination.

Trend toward continuous manufacturing systems.

5. Use of Novel Polymers and Smart Excipients

Incorporation of smart polymers like:

HPMC variants
Eudragit series
Natural gums (guar gum, xanthan gum)
Focus on natural and biodegradable excipients for sustained release layer.
Mucoadhesive and floating bilayer tablets for targeted gastric retention.

6. Lifecycle Management & Product Differentiation

Pharmaceutical companies are using bilayer technology to:
Extend product patent life.
Launch new line extensions of existing drugs.
Offer branded generics with improved formulations.

7. Regulatory and Market Trends

Increasing approval of bilayer tablets by FDA, EMA, and CDSCO for both generic and novel drugs.
Emphasis on Quality by Design (QbD) and robust manufacturing validation.
Growing use in pediatric and geriatric formulations for better control of dosing and swallowing.
Recent Examples (2023–2025):

Product	API(s)	Purpose
Glucovance®	Glibenclamide + Metformin	Diabetes FDC
Exforge HCT®	Amlodipine + Valsartan + HCT	Triple antihypertensive
Bilayer Ibuprofen	IR + SR formulation	Chronic pain and arthritis
Bilayer Zolpidem	Dual-phase sleep aid	IR for sleep onset, SR for sleep maintenance

Future Scope of Bilayer Tablets

Bilayer tablets are gaining strong momentum in the pharmaceutical industry due to their ability to deliver complex drug regimens in a single unit. Their future scope is expanding rapidly across formulation science, patient care, and market strategy.

1. Expansion of Fixed-Dose Combinations (FDCs)

Increasing prevalence of multimorbidity (e.g., diabetes + hypertension) fuels demand for bilayer tablets.
Pharmaceutical companies will continue to develop FDCs to improve patient compliance and reduce pill burden.
Especially valuable in geriatrics, pediatrics, and chronic care.

2. Personalized and Targeted Drug Delivery

Bilayer tablets can be designed for individualized release profiles.
Integration with AI-based formulation platforms for patient-specific regimens.
Ideal for chronotherapy, allowing timed release based on biological rhythms (e.g., morning asthma, nocturnal angina).

3. Integration with Smart Polymers & Nanotechnology

Use of intelligent polymers that respond to pH, temperature, or enzymes.
Bilayer tablets may incorporate nano-carriers (e.g., nanogels, microspheres) in one layer to enhance bioavailability.
Development of mucoadhesive, buccal, or floating bilayer tablets for site-specific action.

4. Continuous and Automated Manufacturing

Future facilities will rely on fully automated bilayer tablet presses with:

Real-time process monitoring (PAT)

AI/ML-based quality control

Enhanced layer bonding control to eliminate delamination risks

Better support for Quality by Design (QbD) and regulatory compliance.

5. Market Expansion in Emerging Countries

As healthcare access improves globally, bilayer tablets will see more adoption in India, Africa, Southeast Asia, etc.

Especially useful in public health programs for TB, HIV, malaria, and NCDs.

6. Strategic Tool for Lifecycle Management

Bilayer technology helps extend the patent life of existing drugs by offering modified-release versions.

Ideal for branded generics and differentiated product lines.

7. Combination with Biologics and Peptides (Emerging Trend)

Research is ongoing to deliver small molecule + peptide combinations in layered tablets.

Though challenging, future bilayer tablets may incorporate oral insulin, GLP-1 analogs, or biosimilars in controlled layers.

Projected Impact Areas

Field	Future Scope
Cardiovascular Therapy	Dual-drug bilayer tablets for BP, heart failure
Diabetes Management	IR + SR of metformin or DPP-4 inhibitors
Mental Health	Sustained action with minimized side effects
Pediatric/Geriatric Use	Easy-to-swallow, low-dose combination layers
Global Health Programs	Simplified regimens for HIV, TB, malaria

Result & Discussion

Bilayer tablets are gaining strong momentum in the pharmaceutical industry due to their ability to deliver complex drug regimens in a single unit. Choosing the right drug(s) is critical in bilayer tablet formulation, as the design relies on specific pharmacokinetic and pharmacodynamic characteristics. Bilayer tablets represent a significant advancement in oral solid dosage forms, offering flexibility, precision, and efficiency in drug delivery. They are especially advantageous when a dual release profile is required or when fixed-dose combinations (FDCs) are used to improve therapeutic outcomes. The successful formulation of bilayer tablets depends on various factors such as drug selection, excipients compatibility, compression technique, and machinery precision. The use of immediate release (IR) and sustained release (SR) layers allows for rapid onset of action followed by prolonged therapeutic effect, enhancing both bioavailability and patient compliance. However, bilayer tablets also present formulation challenges like layer separation, cross-contamination, and weight variation, which require specialized equipment and process optimization. Advances in tablet press technology, smart polymers, and in-process monitoring systems are helping to overcome these limitations, leading to more robust and scalable manufacturing processes. With the increasing demand for combination therapy, chronic disease

management, and personalized medicine, bilayer tablets offer an ideal platform for future innovations in oral drug delivery.

Conclusion

The future scope of bilayer tablets is vast, driven by the need for: Patient-friendly formulations, Precision release control, Efficient drug delivery systems, Regulatory flexibility for FDCs. Bilayer tablets offer a versatile and efficient approach to delivering one or more active pharmaceutical ingredients with distinct release profiles or therapeutic targets. Their ability to combine immediate and sustained action, improve compliance, and reduce dosing frequency makes them an essential tool in modern pharmaceutical practice. In conclusion, bilayer tablets stand as a powerful, patient-centric solution in the advancement of oral drug delivery systems, with strong potential for both present and future pharmaceutical applications.

Reference

1. Shirsand et al., 2012 – Buccal Bilayer Tablets of Atenolol, Title: Formulation and optimization of mucoadhesive bilayer buccal tablets of atenolol using simplex design method, Journal: Int. J. Pharma. Investigation,Highlights: Atenolol bilayer (buccal) tablet designed with HPMC 15 cps + Carbopol + mannitol; achieved ~89.4% release over 9 h with strong bioadhesion and stability confirmed by FTIR
2. Panneer et al., 2011 – Bilayer Buccoadhesive Tablets of Atenolol,Journal: Int. J. Res. Pharma. Sci. Highlights: Used Carbopol 971P + HPMC K100M in matrix layer; exhibited non-Fickian release, with optimized formulations reaching ~90% release in 8 h
3. Parashar & Singh, 2018 – Biphasic Bilayer Tablet of Atenolol,Journal: Asian J. Pharma & Clinic Res.,Highlights: Immediate layer with Crospovidone (≈ 5 %) for rapid release; SR layer using HPMC K15M + gum acacia (1:1) achieved ~91% release by 12 h, following near zero-order kinetics
4. Parashar & Rani, 2022 – Biphasic Atenolol Bilayer Tablet,Book Chapter: Challenges and Advances in Pharmaceutical Research,Highlights: Confirms IR layer with Crospovidone (5 %) good for fast release; SR layer with HPMC K15M + gum acacia provided ~95% release within 12 h
5. Kulkarni & Bhatia, 2009 – Floating Bilayer Tablets (Atenolol + Lovastatin),Journal: Iranian J. Pharma. Res.,Highlights: Though combining atenolol with lovastatin, methodology shows SR atenolol using HPMC K100M + xanthan gum; immediate release for co-drug—demonstrates SR layer principles
6. Stability Study – Amlodipine/Atenolol Bilayer vs Monolayer,Journal: pubmed (2009 study),Highlights: Bilayer tablets showed better stability of atenolol compared to mixed (monolayer) tablets under accelerated conditions
7. Abebe et al. (2014) – Review of Bilayer Tablet Technology,,"Review of bilayer tablet technology", International Journal of Pharmaceutics,Overview of drug delivery strategies, patient compliance, manufacturing challenges (layer adhesion, weight control, delamination) and equipment considerations
8. Mahakal & Malviya (2022) – Advances & Challenges in Bilayer Tablets,"Recent Advancement and Challenges in Bilayer Tablet Technology: An Overview", Current Research in Pharmaceutical Sciences,Focuses on controlled release applications, separating incompatible substances, IR/maintenance dose design, and formulation optimization

9. Sunitha Reddy & Muppa (2021) – Technical Challenges & Possibilities,"A REVIEW OF CHALLENGES AND POSSIBILITIES OF BILAYER TABLET TECHNOLOGY", Int. J. Of Adv. Res.,Highlights practical issues (delamination, hardness, cross-contamination) and strategies to overcome them ijpsr.com.
10. Deshpande et al. (2011) – Emerging Trend,"Bi-layer Tablets – An Emerging Trend: A Review", IJPSR,Discusses advantages like combination therapy, release modulation, and industrial considerations for presses and scaling ,
11. Mishra et al. (2014) – Conceptual Foundation,"A REVIEW ON BI-LAYER TABLETS – AN EMERGING TREND", Journal of Drug Delivery and Therapeutics,Examines sequential release systems, dissimilar apis, and formulation typologies .
12. Sadhu et al. (2019) – Novel Approach Overview,,"Bilayer tablet technology: A novel approach", GSC Biological and Pharmaceutical Sciences,Reviews design principles, sustained/IR layer separation, manufacturing elements, and overcoming incompatibility .
13. Tomar et al. (2015) – Quality & GMP Insights,,"A Review on Novel Approach of Bilayer Tablet", Current Research in Pharmaceutical Sciences,,Introduces bilayer design, API incompatibility resolution, regulatory/GMP requirements, and production techniques
14. QbD-Focused Study: Hydrochlorothiazide Case,"Design and optimization of bilayered tablet of Hydrochlorothiazide using the Quality-by-Design approach",Illustrates bilayer concept with IR and SR layers, use of superdisintegrants in IR, and polymer matrices for SR with QbD methodology